[S-25-1] Overview: Why is the development of new treatment necessary in MG area?

Tomihiro Imai (Sapporo Medical University School of Health Sciences, Japan)

We are now experiencing the drastic changes in treatment strategy against MG. The Japanese clinical guidelines recommended lower dose of chronic steroids and early fast-acting treatment strategy. Recently, clinical trial of eculizumab was performed and the drug has been approved. Even after the proposal for these new strategies, nearly half of the MG patients do not achieve minimal manifestations status with prednisolone ≤5mg/day (a treatment target in Japan). Substantial number of patients are still administered insufficiently reduced oral steroids which hamper patients’ quality of life. Therefore, treatment status of MG is still far from our satisfaction. Fortunately, several new drugs are under development presently. In this symposium, we will discuss over the new drug development and adaptation status in real world clinical setting in United States, Europe and Asia.

[S-25-2] New Drug Development for Myasthenia Gravis

Henry J. Kaminski (George Washington University, USA)

We are now experiencing the drastic changes in treatment strategy against MG. The Japanese clinical guidelines recommended lower dose of chronic steroids and early fast-acting treatment strategy. Recently, clinical trial of eculizumab was performed and the drug has been approved. Even after the proposal for these new strategies, nearly half of the MG patients do not achieve minimal manifestations status with prednisolone ≤5mg/day (a treatment target in Japan). Substantial number of patients are still administered insufficiently reduced oral steroids which hamper patients’ quality of life. Therefore, treatment status of MG is still far from our satisfaction. Fortunately, several new drugs are under development presently. In this symposium, we will discuss over the new drug development and adaptation status in real world clinical setting in United States, Europe and Asia.

[S-25-3] Challenges and developments in MG care in Europe

Maria I Leite^1,2 (1.University of Oxford, UK, 2.Oxford University Hospitals NHS Foundation Trust, UK)

We are now experiencing the drastic changes in treatment strategy against MG. The Japanese clinical guidelines recommended lower dose of chronic steroids and early fast-acting treatment strategy. Recently, clinical trial of eculizumab was performed and the drug has been approved. Even after the proposal for these new strategies, nearly half of the MG patients do not achieve minimal manifestations status with prednisolone ≤5mg/day (a treatment target in Japan). Substantial number of patients are still administered insufficiently reduced oral steroids which hamper patients’ quality of life. Therefore, treatment status of MG is still far from our satisfaction. Fortunately, several new drugs are under development presently. In this symposium, we will discuss over the new drug development and adaptation status in real world clinical setting in United States, Europe and Asia.

[S-25-4] The innovative treatment strategy for patients with myasthenia gravis in Taiwan

Hou-Chang Chiu^1,2,3, Yeh Jiann-horng^2,3, Wang Yuan-ching², Su Ling-chih² (1.Fu-Jen Catholic University Hospital, Taiwan, 2.Shin Kong WHS Memorial Hospital, Taiwan, 3.College of Medicine, Fu-Jen Catholic University, Taiwan)

We are now experiencing the drastic changes in treatment strategy against MG. The Japanese clinical guidelines recommended lower dose of chronic steroids and early fast-acting treatment strategy. Recently, clinical trial of eculizumab was performed and the drug has been approved. Even after the proposal for these new strategies, nearly half of the MG patients do not achieve minimal manifestations status with prednisolone ≤5mg/day (a treatment target in Japan). Substantial number of patients are still administered insufficiently reduced oral steroids which hamper patients’ quality of life. Therefore, treatment status of MG is still far from our satisfaction. Fortunately, several new drugs are under development presently. In this symposium, we will discuss over the new drug development and adaptation status in real world clinical setting in United States, Europe and Asia.

[S-25-5] A possible new treatment for MG: Fc fusion protein, AChR-Fc

Akiyuki Uzawa (Department of Neurology, Graduate School of Medicine, Chiba University, Japan)

We are now experiencing the drastic changes in treatment strategy against MG. The Japanese clinical guidelines recommended lower dose of chronic steroids and early fast-acting treatment strategy. Recently, clinical trial of eculizumab was performed and the drug has been approved. Even after the proposal for these new strategies, nearly half of the MG patients do not achieve minimal manifestations status with prednisolone ≤5mg/day (a treatment target in Japan). Substantial number of patients are still administered insufficiently reduced oral steroids which hamper patients’ quality of life. Therefore, treatment status of MG is still far from our satisfaction. Fortunately, several new drugs are under development presently. In this symposium, we will discuss over the new drug development and adaptation status in real world clinical setting in United States, Europe and Asia.

Session information